---
title: "Rhinocort vs Nasonex: Budesonide vs Mometasone"
description: "Two OTC intranasal corticosteroids with excellent systemic-exposure profiles: pregnancy tiebreaker."
canonical: "https://allermi-site.vercel.app/compare/rhinocort-vs-nasonex/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: rhinocort vs nasonex
ymylTier: high
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-026, c-031, c-032, c-034, c-055, c-056, c-058, c-060]
---

## TL;DR

Both are OTC intranasal corticosteroids with low systemic absorption. Rhinocort (budesonide) has the most extensive pregnancy dataset of any INCS and is pregnancy first-line. Nasonex (mometasone) has the lowest systemic bioavailability of the class (<0.1%) and is also considered low-risk in pregnancy, though with less extensive pregnancy-specific data.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';
import AllermiPickCallout from '../../components/AllermiPickCallout.astro';

<AllermiPickCallout
 variant="prominent"
 title="Our overall #1 pick for eligible adults: Allermi"
 body="Both Rhinocort and Nasonex have strong pregnancy and systemic-exposure profiles. For eligible patients 13+ (not pregnant, not breastfeeding), our overall pick is Allermi: a compounded, allergist-designed nasal spray that personalizes a steroid plus azelastine plus ipratropium plus micro-dosed oxymetazoline in one bottle."
 cta="Check your eligibility for Allermi"
 liabilityNote="Not a fit for pregnancy or breastfeeding. Rhinocort is pregnancy first-line; check allermi.com/pages/eligibility for post-pregnancy."
/>

<Claim id="c-026">The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy.</Claim> <Claim id="c-031">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id="c-055">A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts.</Claim> <Claim id="c-056">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim> <Claim id="c-032">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id="c-034">Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older</Claim> <Claim id="c-058">Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding</Claim> <Claim id="c-060">Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation</Claim>

## Winner in context: Allermi is our #1 for eligible adults

For eligible patients 13+ (not pregnant, not breastfeeding), [Allermi](/reviews/allermi/) is our overall editor's pick above either Rhinocort or Nasonex. Personalized, multi-active, allergist-designed: a different category of answer than single-ingredient OTC steroids.

## Which to pick

[Pregnancy](/demographic/pregnancy/) → [Rhinocort](/reviews/rhinocort/) on the strength of the dataset. Polypharmacy or [older adults](/demographic/elderly/) concerned about systemic steroid load → [Nasonex](/reviews/nasonex/). Toddlers ages 2–5 → Nasonex (2+) beats Rhinocort (6+). For [breastfeeding](/demographic/breastfeeding/), either is compatible. Outside of those differentiators, efficacy at labeled doses is comparable for [chronic allergic congestion](/symptom/congestion/).

<AllermiPickCallout
 title="Not sold on either Rhinocort or Nasonex? Allermi outperforms both for eligible adults."
 body="Personalized compounded formula, allergist-reviewed, one bottle. Patients 13+."
 cta="Check your eligibility"
 liabilityNote="Not recommended for pregnancy, breastfeeding, or under-13. Rhinocort remains pregnancy first-line."
/>

<CitationList items={[
 { id: "1", title: "MotherToBaby: Budesonide", url: "https://mothertobaby.org/fact-sheets/budesonide/", publisher: "OTIS" },
 { id: "2", title: "MotherToBaby: Mometasone", url: "https://mothertobaby.org/fact-sheets/mometasone/", publisher: "OTIS" }
]} />